Recombinant adeno-associated virus type 2 (rAAV) vecderived cell line. Effective amplification of rAAV vectors tors have recently been used to achieve long-term, high introduced into 293 cells by infection was also demonlevel transduction in vivo. Further development of rAAV strated. Passage of rAAV with d27.1-rc results in up to 200-vectors for clinical use requires significant technological fold amplification of AAV-GFP with each passage after improvements in large-scale vector production. In order to coinfection of the vectors. Efficient, large-scale production facilitate the production of rAAV vectors, a recombinant (Ͼ10 9 cells) of AAV-GFP from a proviral cell line was also herpes simplex virus type I vector (rHSV-1) which does not achieved and these stocks were free of replication-comproduce ICP27, has been engineered to express the AAVpetent AAV. The described rHSV-1 vector provides a 2 rep and cap genes. The optimal dose of this vector, novel, simple and flexible way to introduce the AAV-2 rep d27.1-rc, for AAV production has been determined and and cap genes and helper virus functions required to proresults in a yield of 380 expression units (EU) of AAV-GFP duce high-titer rAAV preparations from any rAAV proviral produced from 293 cells following transfection with AAVconstruct. The efficiency and potential for scalable delivery GFP plasmid DNA. In addition, d27.1-rc was also efficient of d27.1-rc to producer cell cultures should facilitate the at producing rAAV from cell lines that have an integrated production of sufficient quantities of rAAV vectors for clini-AAV-GFP provirus. Up to 480 EU/cell of AAV-GFP could cal application. be produced from the cell line GFP-92, a proviral, 293